Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Subscribe
Sign up to receive your free UK subscription to Pf Magazine and our digital newsletters, for all the essential headlines, Jobs of the Week, and thought-provoking features.